Upstream Bio (NASDAQ:UPB) Stock Price Up 4.8% – Should You Buy?

Upstream Bio, Inc. (NASDAQ:UPB) shares were up 4.8% on Wednesday . The stock traded as high as $30.36 and last traded at $30.6070. Approximately 47,436 shares were traded during trading, a decline of 88% from the average daily volume of 402,277 shares. The stock had previously closed at $29.21.

Analyst Ratings Changes

Several analysts have commented on the stock. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Truist Financial started coverage on shares of Upstream Bio in a report on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price target on the stock. Lifesci Capital started coverage on Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price objective on the stock. Evercore ISI began coverage on Upstream Bio in a report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Performance

The company has a market capitalization of $1.65 billion, a PE ratio of -16.27 and a beta of 1.83. The stock’s 50 day moving average is $25.72 and its 200 day moving average is $18.86.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Wednesday, November 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.15. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.65 million. On average, equities research analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Woodline Partners LP boosted its stake in Upstream Bio by 7.9% in the 3rd quarter. Woodline Partners LP now owns 602,252 shares of the company’s stock worth $11,328,000 after purchasing an additional 44,000 shares during the period. Verition Fund Management LLC lifted its holdings in shares of Upstream Bio by 40.3% in the third quarter. Verition Fund Management LLC now owns 47,001 shares of the company’s stock worth $884,000 after buying an additional 13,496 shares in the last quarter. Prelude Capital Management LLC purchased a new stake in shares of Upstream Bio in the third quarter worth about $296,000. Parkman Healthcare Partners LLC boosted its position in shares of Upstream Bio by 17.9% in the third quarter. Parkman Healthcare Partners LLC now owns 843,502 shares of the company’s stock valued at $15,866,000 after acquiring an additional 127,998 shares during the period. Finally, Millennium Management LLC purchased a new position in Upstream Bio during the third quarter valued at approximately $755,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.